Literature DB >> 30890515

[Anti-tumor and immune-modulating effect of Jiawei Sijunzi decoction in mice bearing hepatoma H22 tumor].

Limei Chen1,2, Tong Jin1,2, Chuntao Ning2, Suli Wang3, Lijie Wang2, Jingming Lin2.   

Abstract

OBJECTIVE: To investigate the antitumor activity of Jiawei Sijunzi decoction and study its liver and kidney toxicity and its effect on the immune system in a tumor-bearing mouse model.
METHODS: Hepatoma H22 tumor-bearing mouse models were randomized into model group, cyclophosphamide (CTX) group, and low-, moderate-, and high-dose Jiawei Sijunzi decoction groups (JW-L, JW-M, and JW-H groups, respectively). The antitumor activity of Jiawei Sijunzi decoction was assessed by calculating the tumor inhibition rate and pathological observation of the tumor tissues. Immunohistochemistry was used to detect the expressions of Bax, Bcl-2, Bax/Bcl-2 and caspase-3 in the tumors. The liver and kidney toxicity of Jiawei Sijunzi decoction was analyzed by evaluating the biochemical indicators of liver and kidney functions. The immune function of the tumor-bearing mice were assessed by calculating the immune organ index, testing peripheral blood routines, and detection of serum IL-2 and TNF-α levels using enzyme-linked immunosorbent assay.
RESULTS: Compared with that in the model group, the tumor mass in CTX, JW-M and JW-H groups were all significantly reduced (P < 0.05) with cell rupture and necrosis in the tumors. Immunohistochemistry revealed obviously up-regulated expressions of Bax and caspase-3 and down- regulated expression of Bcl-2 protein with an increased Bax/Bcl-2 ratio in CTX, JW-M and JW-H groups. Treatment with Jiawei Sijunzi decoction significantly reduced Cr, BUN, AST and ALT levels, improved the immune organ index, increased peripheral blood leukocytes, erythrocytes and hemoglobin levels, and up-regulated the levels of TNF-α and IL-2 in the tumor-bearing mice. These changes were especially significant in JW-H group when compared with the parameters in the model group (P < 0.01).
CONCLUSIONS: Jiawei Sijunzi decoction has a strong anti-tumor activity and can improve the liver and kidney functions of tumor-bearing mice. Its anti-tumor effect may be attributed to the up-regulation of Bax, caspase-3, TNF-α and IL-2 levels and the down-regulation of Bcl-2 expression as well as the enhancement of the non-specific immune function.

Entities:  

Keywords:  H22 tumor-bearing mice; Jiawei Sijunzi decoction; antitumor activity; immunity

Mesh:

Substances:

Year:  2019        PMID: 30890515      PMCID: PMC6765632          DOI: 10.12122/j.issn.1673-4254.2019.02.18

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  12 in total

Review 1.  Apoptosis in development.

Authors:  P Meier; A Finch; G Evan
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

Review 2.  Living with death: the evolution of the mitochondrial pathway of apoptosis in animals.

Authors:  A Oberst; C Bender; D R Green
Journal:  Cell Death Differ       Date:  2008-05-02       Impact factor: 15.828

3.  Antiproliferative effect of Dendrobium catenatum Lindley polypeptides against human liver, gastric and breast cancer cell lines.

Authors:  Qiuping Zheng; Daoshou Qiu; Xiaojin Liu; Lei Zhang; Shike Cai; Xuewu Zhang
Journal:  Food Funct       Date:  2015-05       Impact factor: 5.396

Review 4.  Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease.

Authors:  Carla S Coffin; Hughie F Fraser; Remo Panaccione; Subrata Ghosh
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

5.  Bcl-2 overexpression protects against neuron loss within the ischemic margin following experimental stroke and inhibits cytochrome c translocation and caspase-3 activity.

Authors:  Heng Zhao; Midori A Yenari; Danye Cheng; Robert M Sapolsky; Gary K Steinberg
Journal:  J Neurochem       Date:  2003-05       Impact factor: 5.372

6.  Sijunzi decoction-treated rat serum induces apoptosis of side population cells in gastric carcinoma.

Authors:  Jianguang Jia; Yiyu Qin; Ligong Zhang; Chenxu Guo; Yaguo Wang; Xicheng Yue; Jun Qian
Journal:  Exp Ther Med       Date:  2017-11-24       Impact factor: 2.447

7.  Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

Authors:  Jonathan T Sockolosky; Eleonora Trotta; Giulia Parisi; Lora Picton; Leon L Su; Alan C Le; Akanksha Chhabra; Stephanie L Silveria; Benson M George; Indigo C King; Matthew R Tiffany; Kevin Jude; Leah V Sibener; David Baker; Judith A Shizuru; Antoni Ribas; Jeffrey A Bluestone; K Christopher Garcia
Journal:  Science       Date:  2018-03-02       Impact factor: 47.728

Review 8.  Systemic treatment for hepatocellular carcinoma: Still unmet expectations.

Authors:  Dimitrios N Samonakis; Elias A Kouroumalis
Journal:  World J Hepatol       Date:  2017-01-18

9.  Self-regulation of BAX-induced cell death.

Authors:  Denis E Reyna; Evripidis Gavathiotis
Journal:  Oncotarget       Date:  2016-10-11

Review 10.  Role of TNF-alpha in vascular dysfunction.

Authors:  Hanrui Zhang; Yoonjung Park; Junxi Wu; Xiu ping Chen; Sewon Lee; Jiyeon Yang; Kevin C Dellsperger; Cuihua Zhang
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

View more
  3 in total

Review 1.  Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity.

Authors:  Wentao Jia; Lina Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-11       Impact factor: 2.629

2.  Enteral Nutrition Combined with Improved-Sijunzi Decoction Shows Positive Effect in Precachexia Cancer Patients: A Retrospective Analysis.

Authors:  Yueying Li; Yajun Chen; Yaqi Zeng; Jie Dong; Chunlei Li; Yingjie Jia; Yonghua Zhao; Kun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-22       Impact factor: 2.629

3.  Spectrum-Effect Relationship between UPLC Fingerprints and Antilung Cancer Effect of Si Jun Zi Tang.

Authors:  Xiaowei Zhou; Ying Li; Mingyu Zhang; Junjie Hao; Qiong Gu; Haiyang Liu; Wei Chen; Yafei Shi; Bin Dong; Yuanyuan Zhang; Chunyu Li; Guohui Li
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-22       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.